A Caltech Library Service

Preexposure passive transfer predicts plasma antibody levels prevent HIV-I aquisition

Nishimura, Yoshiaki and Shingai, Masashi and Donau, Olivia K. and Plishka, Ronald J. and Buckler-White, Alicia and Mascola, John R. and Nabel, Gary J. and Nason, Martha C. and Montefiori, David and Moldt, Brian and Poignard, Pascal and Diskin, Ron and Bjorkman, Pamela J. and Klein, Florian and Mouquet, Hugo and Burton, Dennis R. and Nussenzweig, Michel C. and Martin, Malcolm A. (2014) Preexposure passive transfer predicts plasma antibody levels prevent HIV-I aquisition. Journal of Medical Primatology, 43 (5). p. 378. ISSN 0047-2565.

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item:


Background: It is widely appreciated that effective human vaccines directed against viral pathogens elicit neutralizing antibodies (NAbs). During the past four years, a new generation of potent broadly reacting neutralizing monoclonal antibodies (mAbs) have been isolated from HIV-I infected individuals. These mAbs typically exhibit great breadth and potency against heterologous HIV isolates when assayed for neutralization in vitro. The passive transfer of anti-HIV l neutralizing antibodies conferring sterilizing immunity to macaques has been used to determine the plasma neutralization titers, which must be present at the time of exposure to prevent acquisition of SIV/HIV chimeric virus (SHIV) infections. Methods: In this study, five recently isolated potent and broadly acting anti-HIV neutralizing mAbs, interacting with the HIV l gp 120 CD4 binding site (VRCO I, 45-46 m^2 and 3BNC 117) or dependent on the gp120 N332 glycan, (10-1074 and PGTl2l) were individually administered to 60 rhesus monkeys, which were challenged intrarectally 24 hours later with either of two different R5-tropic SHIVs. Results: Of the 5 neutralizing mAbs evaluated, PGT121 was clearly the most effective against both viruses. In addition to measuring the plasma concentrations of the different mAbs at the time of challenge and their respective in vivo half lives, the corresponding protective neutralization titers were also determined. By combining the results obtained from 60 challenged animals, we determined that the protective neutralization titer in plasma preventing virus acquisition in 50% of the exposed monkeys was approximately 1:100. Conclusion: These results are informative for establishing a threshold level of protective neutralizing activity to be induced by a prophylactic HIV I vaccine.

Item Type:Article
Related URLs:
URLURL TypeDescription
Diskin, Ron0000-0002-2837-5897
Bjorkman, Pamela J.0000-0002-2277-3990
Nussenzweig, Michel C.0000-0003-0592-8564
Additional Information:© 2014 John Wiley & Sons Ltd. Article first published online: 23 Sep 2014. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Funding AgencyGrant Number
National Institute of Allergy and Infectious DiseasesUNSPECIFIED
Issue or Number:5
Record Number:CaltechAUTHORS:20141124-131258070
Persistent URL:
Official Citation:(2014), Abstracts. Journal of Medical Primatology, 43: 378–431. doi: 10.1111/jmp.12150
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:52110
Deposited By: Ruth Sustaita
Deposited On:25 Nov 2014 00:25
Last Modified:03 Oct 2019 07:39

Repository Staff Only: item control page